Kanya Rajangam - Concepedia

Concepedia

Author

Kanya Rajangam

Amgen (United States)

Also Known As

K Rajangam, K. Rajangam, Kanya Rajangam

32

Publications

1.4K

Citations

13

H-Index

51

Concepts

All Affiliations

Amgen (United States)Northwestern University Unified Szent István and Szent László Hospital Charles University Sheba Medical Center

KR

About

Kanya Rajangam is an author at Amgen (United States) specializing in medicine, oncology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	886
2	Engineering	2	2	506
3	Health Sciences	2	2	355
4	Biomedical Engineering	2	2	506
5	Biochemistry	1	1	123

Kanya Rajangam

×

15

Publications

1.4K

Citations

13

H-Index

	Year	Citations
Heparin Binding Nanostructures to Promote Growth of Blood Vessels Kanya Rajangam, Heather A. Behanna, Michael J. Hui, Nano Letters NanoparticlesTissue EngineeringEngineeringBiofabricationBiomedical Engineering	2006	411
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies David Siegel, Thomas G Martin, A. Nooka, Haematologica PharmacotherapyHematological MalignancyThrombosisHematologyClinical Trials	2013	338
Peptide amphiphile nanostructure–heparin interactions and their relationship to bioactivity Kanya Rajangam, Michael S. Arnold, Mark A. Rocco, Biomaterials Peptide EngineeringPeptide ScienceAmphiphilic SystemBiochemistry	2008	123
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS) Roman Hájek, Tamás Masszi, Maria Teresa Petrucci, Leukemia	2016	118
Capturing the stem cell paracrine effect using heparin-presenting nanofibres to treat cardiovascular diseases Matthew J. Webber, Xiaoqiang Han, S. N. Prasanna Murthy, Journal of Tissue Engineering and Regenerative Medicine NanoparticlesTissue EngineeringEngineeringBiofabricationBiomedical Engineering	2010	95
Modulation of Fluorescence through Coassembly of Molecules in Organic Nanostructures Heather A. Behanna, Kanya Rajangam, Samuel I. Stupp Journal of the American Chemical Society	2006	72
Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational, Retrospective, Cohort Study Kristin Kistler, Jill Kalman, Gagan Sahni, Clinical Lymphoma Myeloma & Leukemia	2016	54
Cardiac Event Rates in Patients with Newly Diagnosed and Relapsed Multiple Myeloma in US Clinical Practice. Kristin D. Kistler, Kanya Rajangam, Gerald A. Faich, Blood	2012	46
A Phase 1 Study of NKX101, an Allogeneic CAR Natural Killer (NK) Cell Therapy, in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndrome (MDS) Carlos Bachier, Gautam Borthakur, Chitra Hosing, Blood	2020	32
A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects with B-Cell Malignancies Michael Dickinson, Nada Hamad, Christian Bryant, Blood	2021	18

Page 1